Introduction: This chapter describes the characteristics of adult patients on renal replacement therapy (RRT) in the UK in 2010. Methods: Data were electronically collected from all 72 renal centres within the UK. Cross-sectional and longitudinal analyses were performed to describe the demographics of prevalent RRT patients in 2010 at centre and national level. Age and gender standardised ratios for prevalence rates per million population per year were calculated. Results: There were 50,965 adult patients receiving RRT in the UK on 31st December 2010. The UK prevalence of RRT (including paediatric patients) was 832 pmp. This represented an annual increase in prevalent numbers of approximately 4% although there was significant variation between centres and regions. From 2009 to 2010 there was a 1.5% increase in the number of patients on haemodialysis (HD), a 3.2% fall in peritoneal dialysis (PD) patients and a 5.4% increase in patients with a functioning transplant. The number of patients receiving home HD has increased 23% since 2009. Median RRT vintage was 5.6 years. The median age was 57.9 years (HD 66.3 years, PD 61.7 years and transplant 51.2 years) compared to 55 years in 2000. Prevalence rates in males exceeded those in females. The most common identifiable renal diagnosis was biopsyproven glomerulonephritis (16.0%), followed by diabetes (14.9%). Transplantation was the most common treatment modality (48%), HD in 44% and PD 8%. Conclusions: The HD and transplant population continued to expand whilst the PD population contracted. There were national, regional and dialysis centre level variations in prevalence rates. Prevalent patients were on average 4 years older than 10 years ago. This has implications for service planning and ensuring equity of care for RRT patients.
Introduction
This chapter presents data on all adult patients on RRT in the UK at the end of 2010. The UK Renal Registry (UKRR) received data returns for 2010 from all five renal centres in Wales, all six in Northern Ireland and all 52 in England. Data from all nine centres in Scotland were obtained from the Scottish Renal Registry. Data on children and young adults can be found in chapter 5.
These analyses of prevalent RRT patients are performed annually to aid clinicians and policy makers in planning future RRT requirements in the UK. It is important to understand national, regional and centre level variation in numbers of prevalent patients as part of the planning process. In addition, knowledge about variation in case mix is also reported to improve understanding of where resources should be focussed to improve equity of provision of RRT in the UK.
The term established renal failure (ERF) used within this chapter is synonymous with the terms end stage renal failure (ESRF) and end stage renal disease (ESRD), which are in more widespread international usage. Patient groups have disliked the term 'end stage' which formerly reflected the inevitable outcome of this disease.
Methods
These analyses relate to the prevalent RRT cohort in the UK in 2010. The cohort was defined as all adult patients receiving RRT on the UKRR database on 31st December 2010. Population estimates were obtained from the UK Office of National Statistics (ONS) [1] .
The number of prevalent RRT patients was calculated for the UK as a whole and for each UK country, using UKRR data from all renal centres. Crude prevalence rates were calculated per million population (pmp) and standardised prevalence ratios were calculated as detailed in appendix D: Methodology used for Analyses (www.renalreg.com/report-area/report 2011/ appendix-D.pdf) for Primary Care Trusts (PCT) in England, Health & Social Care Areas in Northern Ireland, Local Health Boards in Wales and Health Boards in Scotland. These areas will be referred to in this report as 'PCT/HBs'. Briefly, data from all areas were used to calculate overall age and gender specific prevalence rates. The age and gender breakdown of the population in each PCT/HB were obtained from the mid-2010 population estimate based on 2001 Census data from the ONS [1] . The population breakdown and the overall prevalence rates were used to calculate the expected age and gender specific prevalence numbers for each PCT/HB. The age and gender standardised prevalence ratio was the observed prevalence number divided by the expected prevalence number. A ratio below 1 indicated that the observed rate was less than expected given the area's population structure. This was statistically significant at the 5% level if the upper confidence limit was less than 1. Analyses were done for each of the last 6 years and as the prevalent numbers for one year can be small for smaller areas, a combined years' analysis was also done. To enable assessment of whether a centre was an outlier in this regard, funnel plots for smaller and larger populations have been included (appendix D: figures D3, D4) which show the 95% confidence intervals around the national average prevalence. The proportion of non-Whites in each PCT/HB was obtained from the ONS [1] .
Prevalent patients on RRT in 2010 were examined by time on RRT, age group, gender, ethnic origin, primary renal disease, presence of diabetes and treatment modality. (2009 Report appendix H: Coding (www.renalreg.com/report-area/report 2011/appendix-H.pdf). Some centres electronically upload ethnicity coding to their renal information technology (IT) system from the hospital Patient Administration System (PAS). Ethnicity coding in these PAS systems is based on self-reported ethnicity and uses a different coding system to those centres not linked to PAS [2] . For the remaining centres, ethnicity coding is performed by clinical staff and recorded directly into the renal IT system (using a variety of coding systems). For all these analyses, data on ethnic origin were grouped into Whites, South Asians, Blacks, Chinese and Others as described in appendix H: Coding (www.renalreg.com/report-area/report/ 2011/appendix-H.pdf). Time on RRT was defined as median time on treatment and was calculated from the most recent start date. Patients without an accurate start date were excluded from this calculation. Analyses were done for the UK as a whole, by UK country, at centre level and split by treatment modality when appropriate. Chi-squared test, Fisher's exact test, linear regression and Kruskal Wallis tests were used as appropriate to test for significant differences between groups. The data were analysed using SAS 9.2.
Results

Prevalent patient numbers and changes in prevalence
The number of patients for each country (table 2.1) was calculated by adding the patient numbers in each renal centre and these differ marginally from those quoted elsewhere when patients are allocated to geographical areas by their individual postcodes, as some centres treat patients across national boundaries.
There were 50, 965 adult patients and 870 paediatric patients receiving RRT in the UK at the end of 2010, giving a UK population prevalence of 832 pmp (table 2.1) compared with 794 pmp in 2009 [3] . Prevalence rates increased in all four of the UK countries in 2010. For the first time there were no significant differences in prevalence rates between the four countries. PD prevalence remained similar to last year in England and Scotland, a change from the pattern of falling prevalence each year since 1997, and it decreased again in Northern Ireland and Wales. The prevalence of transplanted patients once more increased in the UK. The prevalence rate for each of the UK countries (figure 2.1) shows that Northern Ireland had a higher prevalence rate for patients aged 65þ compared with the other UK countries and that Wales has a higher prevalence rate for patients aged >80 than the other countries. These higher rates were not due to higher numbers of older people in those countries. The prevalence rate in patients aged 80-84 has risen over time from 1,105 per million age related population (pmarp) in 2005 to 1,658 pmarp in 2010 and in patients aged >85 years from 420 pmarp in 2005 to 856 pmarp in 2010. This ageing of the prevalent population is more likely to be due to increasing numbers of older patients starting RRT although there is some effect of improving patient survival as well.
Prevalent patients by RRT centre
Both the number of prevalent patients in each renal centre and the distribution of their treatment modalities varied widely (table 2. 2). Many factors including geography, local population density, age distribution, ethnic composition, prevalence of diseases predisposing to kidney disease and the social deprivation index of that population may contribute to this.
Throughout this chapter, haemodialysis refers to all modes of HD treatment, including haemodiafiltration (HDF). Several centres reported significant numbers of patients on HDF, but other centres did not differentiate this treatment type in their UKRR returns.
Where joint care of renal transplant recipients between the referring centre and the transplant centre occurred, the patient was allocated to the centre which last saw the patient, usually the referring centre. Thus the number of patients allocated to a transplant centre is often lower than that recorded by the centre itself and as a converse pre-emptively transplanted patients are sometimes allocated to the transplanting centre rather than the referring centre if no transfer out code has been sent through. Queries and updated information is welcomed by the UKRR at any point during the year if this has occurred.
Changes in prevalence
Overall growth in the prevalent UK RRT population from 2009 to 2010 was 4% (table 2. 3) which has been fairly consistent over the last 10-15 years (figure 2.2). Most of the growth in the prevalent RRT population was due to a continued increase in the prevalent RRT population in England and Scotland, with slower growth in the prevalent RRT populations in Wales and Northern Ireland.
The prevalent growth per million population (pmp) disguises the differential growth in RRT modalities (HD, PD and transplant) and is shown in Castledine/Casula/Fogarty (table 2.3) . Smaller centres will show relatively large percentage changes in prevalence in either direction due to only small fluctuations in incidence numbers or numbers of deaths, particularly when growth in one year only is examined. The decline in prevalent patients on PD was evident at 38 of the 72 renal centres (data not shown) in the UK and PD numbers declined slightly across all the 4 UK countries. The prevalence rate per million population for each centre was calculated using a derived catchment population. This was calculated from the postcode of each prevalent patient in 2007 and the population within that postcode assigned to the renal Castledine/Casula/Fogarty The need for RRT depends on many factors such as predisposing conditions but also social and demographic factors such as age, gender, social deprivation and ethnicity. Hence comparison of crude prevalence rates by geographical area can be misleading. This section, as in previous reports, uses age and gender standardisation to compare RRT prevalence rates. The ethnic minority profile is also provided to help understand the differences in standardised prevalence ratios (SPR). The impact of social deprivation was analysed in the 2003 UKRR Report [4] . There were substantial variations in the crude PCT/ HB prevalence rate pmp, from 489 pmp (Shetland, population 22,500) to 1,810 pmp (Brent, population 256,500). There were similar variations in standardised prevalence ratios (ratio of observed: expected prevalence rate given the age/gender breakdown of the PCT/HB) from 0.54 (Isle of Wight, population 140,200) to 2.45 (Brent) (table 2.5). Confidence intervals are not presented for the rates per million population for 2010 but figures D3 and D4 in appendix D (www.renalreg.com/reportarea/report 2011/appendix-D.pdf) can be used to determine if a PCT/HB falls within the range representing the 95% confidence limit of the national average prevalence rate. The annual standardised prevalence ratios were inherently more stable than the annual standardised incidence ratios (chapter 1).
Factors associated with variation in standardised prevalence ratios in Primary Care Trusts (PCT) in England, Health and Social Care Areas (HB) in Northern Ireland, Local Health Boards in Wales (HB) and Health Boards in Scotland (HB) Geographical considerations and ethnicity were the major factors underlying the variation in SPRs (table 2.5). In 2010, there were 56 PCT/HBs with a significantly low SPR, 72 with a 'normal' SPR and 48 with a significantly high SPR. The areas with high and low SPRs have been consistent over the last few years. They tend to reflect the demographics of the regions in question such that urban, ethnically diverse populations especially when coupled with areas of deprivation have the highest prevalence rates of renal replacement therapy. Mean SPRs were significantly higher in the 58 PCT/HBs with an ethnic minority population greater than 10% than in those with lower ethnic minority populations (p < 0.0001). The SPR (correlation coefficient r ¼ 0.82 p < 0.001) was positively correlated with ethnicity. In 2010 for each 10% increase in ethnic minority population, the age standardised prevalence ratio increased by 0.20 and this would result in increased prevalent patient numbers. In figure 2.3, the relationship between the ethnic composition of a PCT/HB and its SPR is demonstrated.
Only 6 of the 119 PCT/HBs with ethnic minority populations of less than 10% had high SPRs: Abertawe Bro Morgannwg University, Aneurin Bevan, Belfast, Cwm Taf, Plymouth and Rotherham. Forty-two of the 58 PCT/HBs with ethnic minority populations greater than 10% had high SPRs (72%), whereas only 2 had low SPRs (Medway and Surrey). Medway and Surrey have lower socio-economic deprivation than many areas with higher than average ethnic minority populations which might explain their unexpectedly lower rates. Not all PCT/HBs with high (>15%) ethnic minority populations also had higher than expected RRT prevalence rates; Westminster and Kensington had rates similar to average (1.03 and 0.93 respectively 2005-2010) possibly due to lower levels of social deprivation in these areas. The standardised prevalence ratios in each region of England and in Wales, Northern Ireland and Scotland are presented in table 2.6. North East England, North West England, East of England, South East England, South Central and South West England have lower than expected prevalence rates of RRT given the age and gender of their populations and this pattern has been similar for the last 5 years. West Midlands, London and Wales have higher than expected prevalence rates of RRT given the age and gender of their populations and again this pattern has remained similar for the last 5 years. Scotland and Northern Ireland previously had higher than expected prevalence rates but in more recent years are similar to their expected Castledine/Casula/Fogarty rates. Yorkshire and East Midlands previously met expected prevalence rates but these have fallen to lower than expected in the last 2 years. There was marked variation (30-fold) in prevalence rates in over 80 year olds between PCT/HBs.
Case mix in prevalent RRT patients
Time on RRT Table 2 .7 shows the median time, in years, since starting RRT of prevalent RRT patients on 31/12/2010. Median time on RRT for all prevalent patients was 5.6 years. (For patients who recovered for >90 days and then subsequently restarted RRT the median time from the start of RRT was calculated from the most recent start date.) Patients with functioning transplants had survived a median of 10.3 years on RRT whilst the median time on RRT of HD and PD patients was significantly less (3.2 and 2.0 years respectively p < 0.001). The median time on RRT increased for both transplant and haemodialysis patients over the past 6 years (additional 0.7 and 0.5 years respectively) but not for peritoneal dialysis patients.
Age
The median age of prevalent UK patients on RRT at 31st December 2010 was slightly higher (57.9 years) O/E ¼ observed/expected prevalence rate ratio given the age/gender breakdown of each region population (60 vs. 66 years). The differing age distributions of the transplant and dialysis populations are illustrated in figure 2.4, demonstrating that the age peak for prevalent dialysis patients is around 27 years later than for prevalent transplant patients. In the UK on 31st December 2010, 62% of patients aged under 65 years on RRT had a functioning transplant (table 2.14) compared with only 24% aged 65 years and over. This was similar in all four UK countries.
Gender
Standardising the age of the UK RRT prevalent patients by using the age and gender distribution of the UK population by PCT/HB (from ONS mid-2010 population estimates), allowed estimation of crude prevalence rates by age and gender (figure 2.5). This shows a progressive increase in prevalence rate with age, peaking at 2,007 pmp (a slight increase from 1,912 pmp in 2009) in the age-group 70-74 years before showing a reducing Castledine/Casula/Fogarty 94% ethnicity completeness in England in 2010. Ethnicity completeness is generally slightly worse in prevalent HD patients with the best ethnicity completeness recorded for prevalent transplant patients, this may relate to the fact that the intensive work-up for transplantation may increase the recording of data. In 2010, 17.7% of the prevalent UK RRT population (with assigned ethnicity) were from ethnic minorities (20.8% in England). The proportions in Wales, Scotland and Northern Ireland were very small, although there was a high level of missing ethnicity data in Scotland. This compared with approximately 12% [1] of the UK general population who were designated as belonging to an ethnic minority. The number of patients reported to the UKRR as receiving RRT and belonging to an ethnic minority has doubled in the last 5 years which may be due to improvements in coding of ethnicity as well as increasing incidence of ERF and increased referral rates in these populations.
Amongst the centres with more than 50% returns, there was wide variation between centres with respect to the proportion of patients from ethnic minorities, ranging from 0.5% in one centre (Carlisle) to over 50% in London Barts (58.7%) and London West (54.4%). Three centres have over 40% of prevalent patients from ethnic minorities, Bradford (41.1%), London Kings (45.8%), London Royal Free (48.3%). Centres with an ethnic minority population greater than 10% had higher numbers of prevalent patients on RRT, both on dialysis and with functioning transplants. Fifty-seven percent of transplanting centres had an ethnic minority population greater than 10% compared with 25% of non-transplanting centres.
As would be expected, ethnicity also impacted the median age of the prevalent cohort. Those centres with an ethnic minority population of >10% had a slightly lower median age (57 years vs. 59 years).
Primary renal diagnosis
Data for primary renal diagnosis (PRD) were not sent in 2.5% of patients (3.3% in 2009) and there remained a marked inter-centre difference in completeness of data returns. Where centres had 550% primary renal diagnosis data not sent they were excluded from the following analyses. The UKRR is also concerned about some centres with very high rates of primary renal diagnosis uncertain (EDTA codes 00 and 10). It is accepted that there will inevitably be a number of patients with uncertain aetiology and that the proportion of these patients will vary between clinicians and centres as the definitions Appendix H ethnicity coding of renal vascular disease, hypertensive nephropathy and chronic glomerulonephritis (GN) without tissue diagnosis remain relatively subjective. However, some centres with very high rates of uncertain diagnosis appear to also have fewer patients with the more objective diagnoses such as polycystic kidney disease or biopsy-proven GN. It is believed that the software in these centres defaults any missing data to 'uncertain' (EDTA code 00). This issue has been raised with the centres and software suppliers in 2010 and although not completely resolved for the current data collection, the situation has improved markedly. As a result, two centres with 540% 'uncertain' diagnosis (Wirral, Liverpool RI) have been excluded from the inter-centre analysis and the UK and national totals have been adjusted. The three centres with a high rate of primary renal diagnosis uncertain and data not sent have also been excluded from other analyses where PRD is included in the case-mix adjustment. There was wide inter-centre variation in the proportion of primary renal diagnoses not sent in the RRT prevalent population but this is improving in most centres. There were 4 centres with >15% not sent (Brighton 16.6%, Colchester 48.8%, Truro 16.4%, London Royal Free 50.2%). Uncertain primary renal diagnosis also ranged widely between centres and 6 centres had >30% uncertain diagnosis (Bangor 31%, Cambridge 31%, Doncaster 34%, Ipswich 32%, Liverpool RI 38%, Manchester Hope 33%). Biopsy-proven glomerulonephritis remained the most common specific primary renal diagnosis in the 2010 prevalent cohort at 16.0% (table 2.11), although 20.5% of patients had an uncertain diagnostic code. Diabetes accounted for 14.9% of renal disease in the prevalent patients on RRT, although it was more common in the 565-year age-group compared to the younger group (16.8% vs. 13.9%). This contrasted with the pattern seen in incident patients where diabetes is the predominant specific diagnostic code in 24% of new RRT patients. This reflects the different ages and survival of patients with these diagnoses; it is the younger fitter patients who survive longest and contribute highly to the prevalent numbers. Younger patients (age <65 years) are more likely to have a specific diagnosis and far less likely to have renal vascular disease or hypertension as the cause of their renal failure.
The male:female ratio was greater than unity for all primary renal diagnoses. The gender imbalance may be influenced by the presence of factors such as hypertension, atheroma and renal vascular disease, which are more common in males, more common with increasing age and which may increase the rate of progression of kidney disease. As would be expected from the mode of inheritance, autosomal dominant polycystic kidney disease (ADPKD) was a major exception with the ratio approximating unity and this was similar in the incident cohort.
Diabetes
Diabetes included all prevalent patients with type 1 or type 2 diabetes as primary renal diagnosis (ERA-EDTA coding) and did not include patients with diabetes as a comorbidity. This analysis did not differentiate between type 1 and type 2 diabetes as this distinction was not made in the data submitted by some centres.
The number of prevalent patients with diabetes as a primary renal diagnosis increased to 7, 282 representing 14.9% of all prevalent patients (compared to 12.0% in 2004) (tables 2.12 and 2.13). The median age at start of RRT for patients with diabetes was 9 years higher compared with patients without diabetes, although the median age at the end of 2010 for diabetic patients was only 3.5 years higher. This reflected reduced survival for patients with diabetes compared with patients without diabetes on RRT. Median time on RRT for patients with diabetes was less compared with patients without diabetes (3.4 years vs. 6.5 years) and this difference in survival between diabetics and non-diabetics has not changed over the last 5 years. Patients with diabetes starting RRT in Scotland were 4 years younger and in Northern Ireland 3 years older compared with the UK average age of diabetic patients starting RRT. Diabetes as the primary renal diagnosis also influenced the modality distribution. The predominant mode of treatment for patients with diabetes was HD (61%). The percentage of patients with a functioning transplant was much lower in prevalent patients with diabetes than in prevalent patients without diabetes (30% vs. 52%). However this has increased since 2004 when only 26% of patients with diabetes had a functioning transplant. As would be expected, this difference was even more pronounced for older patients with diabetes (age 565 years) (table 2.13), with only 8.7% of older prevalent patients with diabetes having a functioning transplant compared with 27.3% of their non-diabetic peers. In Northern Ireland, only 21% of prevalent patients with diabetes had a functioning transplant compared with the UK average of 30% although Northern Ireland diabetic patients were older. More prevalent patients without diabetes were on home dialysis therapies (home HD and PD 18.5%) compared with prevalent patients with diabetes (15.1%).
Modalities of treatment
Transplantation was the most common treatment modality (48%) for prevalent RRT patients in 2010, followed closely by centre-based HD (44%) in either hospital centre (22%) or satellite unit (21%) (figure 2.6). Home therapies made up the remaining 9% of treatment therapies, largely PD in its different formats (8%) which was similar to 2009. Home therapies are now being used by 17.6% of prevalent dialysis patients (2.9% home HD and 14.7% PD). The proportion on continuous ambulatory peritoneal dialysis (CAPD) and automated PD (APD) was 3.9% and 3.7% respectively, though the proportion on APD may be an under-estimate due to centre coding issues which mean the UKRR cannot always distinguish between these therapies. The term CAPD has been used for patients receiving nondisconnect as well as disconnect CAPD systems, because the proportion of patients using non-disconnect systems was very small. The number of patients on home HD has stopped falling, rising 23% since 2009 (636 to 780 patients).
As mentioned earlier, treatment modality was related to patient age. Younger patients (age <65 years), were more likely to have a functioning transplant (61.6%) when compared with patients aged over 65 years (23.7%) (table 2.14). HD was the principal modality in the older patients (67.2%).
Figure 2.7 shows the effect of age on modality distribution. With increasing age beyond 64 years, transplant prevalence reduced, whilst HD prevalence increased. The proportion of each age group treated by PD remained fairly stable across the age spectrum.
The proportion of prevalent dialysis patients receiving HD, ranged from 68.5% in Derby to 100% in Colchester (table 2.15).
The number of centres with no prevalent HD patients reported as being treated at satellite units decreased in 2010, although some of these centres were unable to record these data in their renal IT systems. Overall the proportion of dialysis patients treated in a satellite haemodialysis centre has increased to 40% this year compared to 36% in 2009 and 35% in 2007. Although there are satellite units in Scotland, the data are not provided to distinguish between main centre and satellite unit haemodialysis except for the Glasgow renal centre. In 2010, the number of centres that had more than 50% of their HD activity taking place in satellite units increased to 27 (table 2.15 and figure 2.8). There was also wide variation between centres in the proportion of PD patients on APD treatment, ranging from 0 to UK Castledine/Casula/Fogarty 
Home haemodialysis
The use of home HD as a RRT peaked in 1982 when almost 2,200 patients were estimated to be on this therapy, representing 61% of HD patients reported to the ERA-EDTA registry at that time. The fall in the use of this modality to just 445 patients (2.4% of HD patients) in 2006 was probably due to an increase in the use of renal transplantation and also the expansion of hospital HD provision with the introduction of satellite units. In the last seven years there has been renewed interest in home HD and a target of 15% of HD patients on this modality has been suggested [5] . Equipment changes and patient choice has helped drive this change. Since 2006 there has been a gradual increase in the proportion of prevalent patients receiving haemodialysis in their own homes so that in 2010 it reached 3.4% of HD patients (n ¼ 780, figure 2.2 and table 2.15). These numbers may be an under-estimate as some centres have been unable to submit data for patients coded as home HD and work is on-going to address this.
In 2010, the percentage of dialysis patients receiving home HD varied from 0% in 13 centres, to greater than 5% in 8 centres, namely Bangor 9.7%, Brighton 6%, Bristol 5.6%, Cardiff 5.5%, Derby 14.3%, London Guys 5.9%, Manchester RI 12.1% and Sheffield 7.1% (table 2.15).
The increase in home HD patients was mainly due to an increase in Wales plus the Northern Ireland renal centres in Belfast, Derry and Ulster. Improved coding of patients on home HD in Wales resulted in an increase in the number of prevalent patients returned to the UKRR, in particular the 2008 numbers were an underestimate of the true number of patients in Cardiff [3] , were seen at Bangor (9.7% vs. 4.6%) and Derby (14.3% vs. 4.2%). In 19 centres, the proportion of prevalent dialysis patients on home HD decreased slightly in 2010 compared with the previous year.
Change in modality
The relative proportion of RRT modalities in prevalent patients has changed dramatically over the past decade. The main features are depicted in figure 2.9, which describes a sustained decrease in the proportion of patients treated by PD after 2000. Possible explanations for this change include recently published evidence indicating that the equivalent survival demonstrated between HD and PD was only maintained for the first 2-3 years [6] and recent concerns regarding the risk of encapsulating peritoneal sclerosis which might result in patients being switched from PD to HD after a fixed time interval. Analysis of UKRR data has shown that this is not the explanation as the vintage of PD patients has not changed substantially over the last 8 years. The reduction in prevalent PD patients was due to a decrease in the number of new patients who were started on peritoneal dialysis in 2009 and 2010 and also to the declining proportion of patients starting RRT on peritoneal dialysis since 2001. The determinants of this pattern may be multi-factorial and include: an increase in HD capacity with the proliferation of satellite units, the effect of patient or physician choice regarding the treatment modality at start of RRT, the general health and fitness of patients starting RRT some of whom may be deemed less capable of undertaking PD independently and the rise in the number of patients receiving a live related transplant who may otherwise have gone onto PD. With the advent of assisted PD (more commonly used in France) [7] in conjunction with the increasing age of PD patients, there may be potential for some reversal or slowing in this decline. The proposed introduction of dialysis tariffs in England may well result in further changes to the types of treatment patients receive in England.
The proportion of patients treated with HD was still increasing, although at a slower rate, and it may have begun to plateau from 2007 onwards. The proportion of patients with a functioning transplant had been on a slight downward trend but this has reversed since 2007, probably due to continued increases in living organ and non-heart beating donation [8] .
Figure 2.10 depicts in more detail the modality changes in the prevalent dialysis population during this time and highlights a sustained reduction in the proportion of patients treated by CAPD. There was a sustained increase in the proportion of prevalent HD patients treated at satellite units with a steady decline in hospital centre haemodialysis since 2004.
International comparisons
Prevalence rates in the UK are similar to those in most other Northern European countries but lower than in Southern Europe and Belgium and far lower than in the USA (figure 2.11).
Summary
There continued to be growth across the UK in prevalent patients on RRT with regional and centre level variation. For the first time this year there was no real difference in prevalence rates between the four nations of the UK. In general, areas with large ethnic minority populations had higher standardised prevalence ratios. There were increasing numbers of patients on HD and with a functioning transplant and falling numbers on PD. The prevalence rate in the over 80 year olds has doubled since 2005. There have been substantial increases in home HD use in some areas although several centres are still unable to offer this modality. 
